Location History:
- Lausanne, CH (2018 - 2021)
- Epalinges, CH (2018 - 2024)
Company Filing History:
21 out of 541 
13 out of 21 
1 out of 1 Years Active: 2018-2024
Title: Patricius Hendrikus Cornelis Van Berkel: A Pioneer in Antibody Research
Introduction: Patricius Hendrikus Cornelis Van Berkel is a notable inventor based in Epalinges, Switzerland. He has made significant contributions to the field of biochemistry, particularly with his innovative research and development of antibodies. With a remarkable portfolio of 24 patents, he is recognized for his groundbreaking work in therapeutic applications.
Latest Patents: Among his latest patents are the Anti-IL13Rα2 antibodies, which specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13Rα2) protein. This patent outlines associated methods for production and potential uses for treatment. Another recent invention is the Pyrrolobenzodiazepine-antibody conjugates, providing a novel ligand structure that combines antibodies with therapeutic agents, enhancing targeted delivery and efficacy.
Career Highlights: Van Berkel has had a distinguished career, having worked with renowned institutions such as Medimmune Limited and ADC Therapeutics SA. His efforts in the pharmaceutical industry have advanced the understanding of antibody applications in treating various diseases.
Collaborations: Throughout his career, Van Berkel has collaborated with talented colleagues, including Philip Wilson Howard and Jens Wuerthner. These partnerships have undoubtedly contributed to the success of his research and the development of his numerous patents.
Conclusion: Patricius Hendrikus Cornelis Van Berkel's innovative work in antibody research underscores the importance of collaboration and creativity in scientific advancement. His 24 patents reflect his commitment to improving therapeutic solutions and the future of biomedical research.